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Objectives. This study was undertaken to examine the relation
of in vivo low density lipoprotein (LDL) oxidation and other lipid
risk factors to coronary reactivity in normal subjects.
Background. Experimental studies have shown that oxidized
LDL (ox-LDL) particles are injurious to the vascular wall by
impairing its normal vasodilator function.
Methods. We used noninvasive positron emission tomographic
(PET) imaging with intravenous dipyridamole to measure coro-
nary flow reserve, a marker of coronary endothelial and smooth
muscle function, in 30 healthy men (mean [6SD] age 34.4 6 3.2
years). As a marker of in vivo LDL oxidation, the autoantibody
titer against ox-LDL was measured by the enzyme-linked immu-
nosorbent assay method.
Results. Plasma levels of autoantibody titer against ox-LDL
were inversely associated with coronary flow reserve (r 5 20.42,
p 5 0.023). High LDL cholesterol levels (above median >3.0
mmol/liter) were associated with a low coronary flow reserve only
in subjects expressing simultaneously high levels of ox-LDL titer
(above median). Subjects with simultaneously high levels of LDL
cholesterol and ox-LDL titer had lower coronary flow reserve
values than subjects in other groups (3.89 vs. >5.0 in other
groups, p 5 0.066).
Conclusions. These data provide evidence for the role of
ox-LDL in affecting the coronary reactivity in vivo and support the
concept that oxidative modification of LDL particles provides a
mechanism by which high LDL concentrations exhibit injurious
effects on the coronary vascular bed.
(J Am Coll Cardiol 1997;30:97–102)
©1997 by the American College of Cardiology
Endothelial dysfunction is an early event in atherosclerosis (1).
In experimental primate models for atherosclerosis, impair-
ment in endothelium-dependent vasodilatory reserve has been
shown (2) to appear before plaque formation. In humans, an
abnormal response to endothelium-dependent vasodilation in
coronary arteries has been observed (3) in subjects with risk
factors for coronary heart disease but without evidence of
atherosclerotic lesions on angiography or intravascular ultra-
sound. Coronary flow reserve, defined as the ratio of pharma-
cologically (by dipyridamole) stimulated maximal coronary
blood flow to basal flow, is an integrating marker of endothelial
function and smooth muscle relaxation and therefore reflects
normal coronary reactivity. Coronary flow reserve can be
measured noninvasively with positron emission tomography
(PET) and intravenous dipyridamole infusion. Previous studies
have shown that coronary reactivity assessed by PET may be
used to detect vascular abnormalities before the angiographic
appearance of atherosclerotic coronary lesions (4) and that
coronary flow reserve is related to serum cholesterol levels
(5,6).
The mechanisms by which hypercholesterolemia causes
vasodilatory dysfunction are not well elucidated, but oxidative
modification of low density lipoprotein (LDL) particles may
have a central role in this process. The detrimental effects of
oxidatively modified lipoproteins on vascular function have
been demonstrated in animal studies (7,8), and it is now
recognized that oxidative modification of LDL occurs in vivo
(9,10). Furthermore, oxidized LDL (ox-LDL) particles cause
in vivo formation of autoantibody (10), which can be isolated
from atherosclerotic lesions (11) and measured in serum (9).
The primary purpose of the present study was to test the
hypothesis that an increase in the titer of autoantibodies to
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ox-LDL representing a biologic marker of enhanced LDL
oxidation in vivo, would be associated with altered coronary
reactivity among healthy young men. Secondly, we assessed the
relation between coronary reactivity and other lipid risk factors
for coronary heart disease.
Methods
Subjects. Thirty healthy men volunteered for the study.
The inclusion criteria were age ,40 years, body mass index
,27 kg/m2, blood pressure ,150/90 mm Hg, nonsmoker, no
history of diabetes and no history of atherosclerotic disease.
The characteristics of study subjects are shown in Table 1.
PET study protocol. All PET studies were performed after
an overnight fast. A myocardial perfusion study was performed
twice, once at rest and once after administration of dipyrida-
mole. Heart rate and the electrocardiogram were monitored
continuously during the studies. Blood pressure was monitored
with an automatic oscillometric blood pressure monitor
(OMRON HEM-705C, Omron Healthcare, Hamburg, Ger-
many) during the PET study. The study protocol was accepted by
the Ethical Committee of Turku University and Turku University
Central Hospital. Each subject gave written informed consent.
Production of [15O]CO and [15O]H2O. For production of
15O, a low energy deuteron accelerator, Cyclone 3, was used
(Ion Beam Application, Louvain-la-Neuve, Belgium); [15O]CO
was produced conventionally (12); and 15O-labeled water was
produced using dialysis techniques in a continuously working
water module (13). Sterility and pyrogen tests for water and
chromatographic analysis for gases were performed to verify
the purity of the products.
Image acquisition, processing and corrections. The pa-
tients were positioned supine in a 15-slice ECAT 931/08-12
tomograph (Siemens/CTI) with a measured axial resolution of
6.7 mm and in-plane resolution of 6.5 mm. To correct for
photon attenuation, a transmission scan was performed for
20 min before the emission scan, with a removable ring source
containing 68Ge (total counts 15 to 30 3 106/plane).
After the transmission scan, the subjects’ nostrils were
closed, and they inhaled [15O]CO for 2 min through a three-
way inhalation flap valve (0.14% CO mixed with room air
(mean [6SD] dose 3,400 6 410 MBq [(92 6 11 mCi]). After
inhalation, 2 min were allowed for CO to combine with
hemoglobin in red blood cells before a static scan for 4 min was
started. During the scan period, three blood samples were
drawn at 2-min intervals, and blood radioactivity was measured
immediately with a well counter (Bicron 3MW3/3). A 10-min
period was allowed for the radioactive decay of [15O]CO
before the flow measurements.
Flow was measured at the baseline and 2 min after the end
of intravenous administration of dipyridamole (0.56 mg/kg
body weight over 4 min); 1,650 6 110 MBq (45 6 3 mCi) of
[15O]H2O was injected intravenously during 2 min (1,670 6
110 MBq at baseline, 1,630 6 110 MBq after dipyridamole);
and a dynamic scan was started for 6 min (six 5-s frames, six
15-s frames and eight 30-s frames). All data were corrected for
deadtime, decay and photon attenuation and reconstructed
into a 128 3 128 matrix. The final in-plane resolution in
reconstructed and Hann-filtered (0.3 cycles/s) images was
9.5 mm (full-width half-maximum).
Calculation of regional blood flow. Regions of interest
were placed on representative transaxial ventricular slices in
each study covering the anterior and lateral free wall of the left
ventricle. The regions of interest were drawn on the images
obtained at rest and copied to the images obtained after
dipyridamole administration. Values of regional myocardial
blood flow (expressed in ml/g tissue per min) were calculated
according to previously published methods using the single-
compartment model (14,15). Mean blood flow values at base-
line and after dipyridamole administration were calculated and
used in the subsequent analysis. The arterial input function was
obtained from the left ventricular time activity curve using a
previously validated method (14), in which corrections were
made for the limited recovery of the left ventricular region of
interest and the spillover from the myocardial signals. Quali-
tative analysis of the PET data did not reveal any regional
Abbreviations and Acronyms
Apo A-I 5 apolipoprotein A-I
Apo B 5 apolipoprotein B
BHT 5 butylated hydroxytoluene
BSA 5 bovine serum albumin
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
Lp(a) 5 lipoprotein(a)
ox-LDL 5 oxidized low density lipoprotein
PBS 5 phosphate-buffered saline
PET 5 positron emission tomography (tomographic)
Table. 1 Characteristics, Lipid Profiles and Flow Variables of 30
Study Subjects
Mean (SD)
Age (yr) 34 (3)
BMI (kg/m2) 23.7 (1.9)
SBP (mm Hg) 114 (11)
DBP (mm Hg) 61 (8)
Lipid variables
Serum cholesterol (mmol/liter) 5.05 (1.39)
HDL cholesterol (mmol/liter) 1.29 (0.31)
TG (mmol/liter) 1.08 (0.70)
Apo B (g/liter) 0.87 (0.34)
Apo A-I (g/liter) 1.60 (0.20)
Lp(a) (mg/liter) 154.1 (71.0)*
LDL particle diam (Å) 274 (16)
Flow variables
Basal flow (ml/min per g) 0.84 (0.13)
Dipyridamole stress flow (ml/min per g) 4.09 (1.57)
Coronary flow reserve 4.87 (1.77)
*Mean (median). Apo 5 apolipoprotein; BMI 5 body mass index; DBP 5
diastolic blood pressure; diam 5 diameter; HDL 5 high density lipoprotein;
LDL 5 low density lipoprotein; Lp(a) 5 lipoprotein(a); SBP 5 systolic blood
pressure; TG 5 triglycerides.
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differences in the distribution of blood flow. Therefore, to
enhance accuracy and statistics of flow measurements, the
average flow of global left ventricular myocardium was calcu-
lated, and no detailed regional analysis was carried out.
Coronary flow reserve was defined as the ratio of myocardial
blood flow after dipyridamole to flow at baseline.
Serum lipoproteins. Venous blood samples were taken
after 12 h of overnight fast during the same week as the PET
study. Serum total cholesterol, high density lipoprotein (HDL)
cholesterol and triglyceride concentrations were measured
using standard enzymatic methods (Boehringer-Mannheim
GmbH, Mannheim, Germany) with a fully automated analyzer
(Hitachi 704, Hitachi Ltd., Tokyo, Japan). HDL cholesterol
was measured after polyethyleneglycol (mv 6000, final concen-
tration 10%) precipitation (16). The LDL cholesterol concen-
tration was calculated using the Friedewald formula (17).
Apolipoprotein A-I (Apo A-I) and apolipoprotein B (Apo B)
were measured by the immunonephelometric method (Behr-
ingwerke, Marburg, Germany). Serum levels of lipoprotein(a)
[Lp(a)] were determined using a commercially available solid-
phase two-site immunoradiometric assay kit [Mercodia Apo(a)
RIA, Mercodia AB, Uppsala, Sweden].
Autoantibodies against ox-LDL. Autoantibody titers of
anti–ox-LDL were measured by enzyme-linked immunosor-
bent assay using 96-well polystyrene microtitration plates
(Nunc, Immunoplate, Roskilde, Denmark) (18,19). Antigens
for this assay included native LDL protected against oxidation
by 0.27 mmol/liter edetic acid and 20 mmol butylated hydroxy-
toluene (BHT) in phosphate-buffered saline (PBS, 10 mmol/
liter sodium phosphate, pH 7.2) and ox-LDL (obtained after
18 h oxidation with 2 mmol/liter CuSO4 and prepared from the
pooled plasma of 10 donors) (20). The wells were incubated
(coated) with 50 ml of native and ox-LDL antigen (5 mg/ml)
(protected from oxidation as noted above) in PBS for 16 h at
4°C. After removal of the unbound antigen and washing of the
wells (three times with PBS 0.5% Tween 20 and three times
with distilled H2O using microtiter plate washer Bio Rad
model 1550), the remaining nonspecific binding sites were
saturated using 2% bovine serum albumin (BSA) in PBS and
20 mmol/liter BHT-1% for 2 h at 4°C. The wells were washed
six times, and 50 ml of serum sample, diluted 1:20 and 1:50, was
added to wells coated with native LDL and ox-LDL and
incubated overnight at 4°C. After incubation, wells were
aspirated and washed six times (as noted above) before an
appropriate immunoglobulin G–peroxidaseconjugated rabbit
antihuman monoclonal antibody (Organon, No. 55220 Cappel)
diluted 1:4,000 (vol/vol) (in buffer PBS 0.27 mmol/liter, edetic
acid 20 mmol/liter, BHT-1%, BSA-0.05% Tween) for 500 ml
was added to each well for 4 h at 4°C. After incubation, the
unbound material from the wells was aspirated, and wells were
washed six times (as above). After this, 500 ml of freshly made
substrate (0.4 mg/ml of o-phenylenediamine [Sigma] and
0.045% H2O2 in 100 mmol/liter acetate buffer pH 5.4) was
added and incubated 5 min at room temperature. The enzyme
reaction was terminated by adding 500 ml of 2 mol/liter H2SO4.
The optical density was measured spectrophotometrically at
492 nm and read with a special microplate reader (Multiskan
MCC/340, Labsystems GmbH, Munich, Germany). To calcu-
late the antibody titer, we used the ratio of the corresponding
spectrophotometric reading of anti–ox-LDL and the anti–
native LDL wells from the same serum sample. Using this
approach, the spectrophotometric readings of anti–native LDL
wells represent the corresponding blanks of anti–ox-LDL wells
and reduce the possible detection of false positive values.
LDL gradient gel electrophoresis. Nondenaturing poly-
acrylamide gradient gel electrophoresis was performed from
frozen (270°C) serum samples using the method of Nichols et
al. (21). The gels with a polyacrylamide gradient from 2% to
12% were cast in our laboratory according to the method of
Rainwater et al. (22) with slight modifications (23). The gels
were stained with Sudan Black B lipid stain and scanned with
a laser scanning densitometer (Personal Densitometer, Molec-
ular Dynamics) using a 50-mm pixel size and 12-bit signal
resolution. The mean particle diameter of the major LDL peak
was determined by comparing the mobility of the sample to the
mobility of a calibrated LDL preparation run on each gel.
Coefficients of variation for the intragel and intergel precisions
of the control sample used were 1.2% and 3.5%, respectively.
Statistical methods. Results are expressed as mean
value 6 SD (unless stated otherwise). The associations be-
tween study variables were assessed by calculating Spearman
rank order correlation coefficients. The Student t test, non-
parametric Mann-Whitney U test or analysis of variance with
Bonferroni’s multiple comparison procedure were used in
group comparisons, as appropriate. All statistical tests were
performed with the Statistical Analysis System (SAS) (24).
Results
Subjects. All subjects were normotensive, nondiabetic, and
nonsmokers. The physical characteristics, lipid profiles and
flow variables of the study subjects are shown in Table 1. The
autoantibody titers against ox-LDL averaged 2.86 6 1.48
(arbitrary units).
Associations between coronary reactivity and risk factors.
Coronary flow reserve was significantly associated with ox-LDL
(r 5 20.42, p 5 0.023), and tended to correlate with serum
total cholesterol concentration (r 5 20.33, p 5 0.076).
Six of the study subjects (lowest quintile of the present study
cohort) had low (,2.8) coronary flow reserve values compared
with the results of several previous PET studies (4,25–31),
which have reported about threefold to sixfold flow increases
after pharmacologic stimulation by dipyridamole in normal
volunteers or in normal myocardium of patients with coronary
heart disease. To examine whether abnormally low coronary
flow reserve values would be associated with deviations in the
lipid profile, we compared the lipid variables in the six men
with low coronary flow reserve with others (Table 2). Those
men with low coronary flow values had significantly higher
autoantibody titers against ox-LDL and higher serum total
cholesterol, LDL cholesterol and Apo B concentrations than
the other men. The two groups did not differ significantly with
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respect to potential confounders (i.e., age, body mass index,
blood pressure or heart rate) (data not shown).
The combined effects of ox-LDL and LDL cholesterol were
studied by classifying the study subjects into four groups
according to high or low values of ox-LDL titer and LDL
cholesterol concentration using the median values as cutpoints.
These cutpoints were 3.00 mmol/liter and 2.50 for LDL
cholesterol and ox-LDL titer, respectively. Coronary flow
reserve in these groups is shown in Figure 1. High LDL
cholesterol levels were associated with low coronary flow
reserve only in subjects expressing simultaneously high levels
of ox-LDL titer; the group with high LDL cholesterol levels
and high ox-LDL titer values tended to have lower coronary
flow reserve than the other groups (3.89 6 1.62 vs. .5.0 in
other groups, overall comparison p 5 0.066).
Interrelation between ox-LDL, LDL particle size and other
risk factor variables. The autoantibody titer to ox-LDL was
directly associated with serum total cholesterol (r 5 0.55, p 5
0.002), LDL cholesterol (r 5 0.54, p 5 0.002) and Apo B
concentrations (r 5 0.48, p 5 0.008). No significant correlation
was seen between ox-LDL titer and LDL particle size (r 5
20.04, p 5 0.83), but LDL particle size correlated significantly
with HDL cholesterol (r 5 0.56, p 5 0.0015), triglycerides (r 5
20.56, p 5 0.0013), Apo B (r 5 20.43, p 5 0.018) and Apo A-I
(r 5 0.48, p 5 0.007).
Discussion
In the present study, we showed in young healthy men that
the coronary vascular vasodilatory response to dipyridamole is
related to the autoantibody titer against oxidatively modified
LDL. This finding provides evidence for an in vivo role of LDL
oxidation in affecting coronary reactivity in humans and is in
line with the hypothesis that oxidatively modified LDL is
injurious to the vascular wall (7). In concord with our results,
Anderson et al. (32) found that angiographically studied
endothelium-dependent coronary vasomotion was related to
the in vitro susceptibility of LDL to oxidation. Furthermore,
Heitzer et al. (19) observed an inverse relation between plasma
level of autoantibody titer against ox-LDL and acetylcholine-
induced increase in forearm blood flow. In the present study,
high LDL cholesterol level seemed to be associated with low
coronary flow reserve only in subjects expressing simulta-
neously high ox-LDL titer. This finding supports the concept
that oxidative modification of LDL particles provides a mech-
anism by which high LDL concentrations exhibit injurious
effects on the coronary vascular bed. Kugiyama et al. (33)
consistently found that native LDL had no inhibitory effect on
endothelial function, whereas ox-LDL completely abolished
vascular relaxation after acetylcholine administration. In addi-
tion, an intervention trial by Anderson et al. (34) showed the
greatest improvement in endothelial function in hypercholes-
terolemic patients receiving both cholesterol-lowering and
antioxidant treatments. We previously showed (6) that young
men with familial hypercholesterolemia have lower coronary
flow reserve values than healthy control subjects, suggesting a
detrimental effect of high cholesterol concentration on vaso-
dilatory function in coronary arteries. In the present study,
healthy men with low coronary flow reserve also expressed
higher total cholesterol and LDL cholesterol levels than oth-
ers. This finding may be explained by the observations of
Ohara et al. (35), who showed that hypercholesterolemia
stimulates endothelial production of superoxide radicals,
which not only enhance the oxidation of LDL particles within
arterial wall but also directly inactivate nitric oxide and there-
fore interfere with endothelium-dependent vasodilation (36).
Unexpectedly, high ox-LDL titers in the presence of low LDL
cholesterol concentrations were not associated with low coro-
nary flow reserve values. This result may relate to the small
number of subjects in the group with high levels of ox-LDL
titer and low levels of LDL cholesterol or to somewhat lower
mean ox-LDL titer levels in this group than the group with
high levels of ox-LDL titer and LDL cholesterol. Prospective
studies are needed to assess the question whether differences
Figure 1. Coronary flow reserve in groups defined by low or high LDL
cholesterol and ox-LDL levels (median value used as cutpoint). Study
groups: I 5 low LDL cholesterol and low ox-LDL titer (n 5 11); II 5
low LDL cholesterol and high ox-LDL titer (n 5 4); III 5 high LDL
cholesterol and low ox-LDL titer (n 5 4); IV 5 high LDL cholesterol
and high ox-LDL titer (n 5 11). The autoantibody titer averaged
1.85 6 0.47, 3.28 6 0.31, 1.49 6 0.52 and 4.23 6 1.40 arbitrary units in
groups I, II, III and IV, respectively.
Table 2. Comparison of Lipid and Lipoprotein Values (by p value)
in Subjects With Low or High Coronary Flow Reserve




(n 5 24) p Value
Ox-LDL titer 4.00 (2.08) 2.60 (1.18) 0.033
Apo B (g/liter) 1.13 (0.29) 0.81 (0.33) 0.040
TC (mmol/liter) 6.07 (1.06) 4.79 (1.37) 0.043
LDL cholesterol (mmol/liter) 4.20 (1.06) 3.03 (1.28) 0.048
HDL/TC ratio 0.21 (0.08) 0.29 (0.10) 0.100
Lp(a) (mg/liter)* 220.0 (192.5) 137.1 (43.0) 0.139
TG (mmol/liter) 1.33 (0.70) 1.02 (0.70) 0.152
LDL particle diam (Å) 267.1 (15.9) 275.7 (15.7) 0.242
Apo A-I (g/liter) 1.64 (0.19) 1.59 (0.20) 0.560
HDL cholesterol (mmol/liter) 1.26 (0.35) 1.29 (0.31) 0.798
*Mean (median). Abbreviations as in Table 1.
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in LDL cholesterol concentrations modify the risk of coronary
heart disease associated with high ox-LDL levels.
Oxidized LDL. Oxidized LDL contains lysophosphatidyl-
choline, a product formed from phosphatidylcholine during
lipid peroxidation. In vitro studies (33,37) have shown that
lysophosphatidylcholine is the principal substance for the
impairment of endothelium-dependent vascular relaxation.
Lysophosphatidylcholine has been shown to induce acceler-
ated degration of nitric oxide by increased endothelial super-
oxide anion production (38) and to inhibit nitric oxide release
(39) or nitric oxide synthase (40). In addition to endothelium-
dependent mechanisms ox-LDL also may cause disturbances in
vasomotion due to direct interaction on vascular smooth
muscle cells (41). Evidence is accumulating to indicate that
oxidatively modified LDL particles may have an essential role
in the pathogenesis of atherosclerosis. Oxidation of LDL has
been particularly implicated in the formation of fatty streak in
the arterial intima. Ox-LDL has diminished affinity to the LDL
receptor and is more readily bound to the scavenger receptor
in the macrophages, thus ensuring the formation of foam cells
(42). In concord, observational studies have suggested that in
vivo oxidation may be important in the progression of athero-
sclerosis. Salonen et al. (18) reported that a high titer of
autoantibodies against malondialdehyde lysine, an epitope of
oxidized LDL, was an independent predictor of the progres-
sion of carotid atherosclerosis in Finnish men during a 2-year
follow-up period. Maggi et al. (43) observed a higher titer of
autoantibodies against copper-oxidized and malondialdehyde-
derivatized LDL in patients with severe carotid atherosclerosis
than in matched control subjects. Other case-control studies
have demonstrated higher titer of autoantibodies against ox-
LDL in patients with coronary heart disease (44) and essential
hypertension (45). The findings of the present study suggest
that elevated levels of ox-LDL may also be involved in the
initiation phase of atherosclerotic disease by affecting the
coronary reactivity in healthy men.
Effect of dipyridamole. We used dipyridamole as a vasodi-
lating agent to test coronary vascular function. Dipyridamole
increases interstitial adenosine concentration in vascular
smooth muscle cells and leads to relaxation of coronary
resistance vessels. The vasodilation induced by adenosine has
been considered to occur through endothelium-independent
mechanisms, based on direct stimulation of A2-adenosine
receptors on vascular smooth muscle cells. Adenosine-
mediated vasodilation is also partly endothelium dependent
because it has been shown (46) that increased shear stress
associated with increased flow after administration of adeno-
sine will induce the release of vasodilating substances from
endothelial cells and elicit more prominent vasodilation in the
vessels with normal endothelial function. Therefore, the coro-
nary flow reserve, as assessed by intravenous dipyridamole
infusion, most likely reflects the combined effect of vascular
smooth muscle relaxation and endothelial-mediated vasodila-
tory function (4,28,29) and has been suggested (4) to be a
measure of early atherosclerotic changes.
LDL particle size. The relation between LDL particle size
(as measured by gel electrophoresis) and coronary reactivity
has not been previously examined. We found no relation
between LDL particle size and coronary flow reserve in our
study group of young men. Several in vitro studies (47–49)
have shown that small, dense LDL particles are susceptible to
oxidative modification. In addition, a recent in vivo study (50)
suggested a higher titer of malondialdehyde-modified LDL
among patients with predominantly small, dense LDL particles
(subclass pattern B). However, we found no significant associ-
ation with LDL particle size and ox-LDL titer, which may be
due to the fact that most of our subjects had a large LDL mean
peak particle size (only two subjects expressed subclass pattern
B defined by LDL peak particle diameter ,255 Å). Neverthe-
less, LDL particle size was significantly associated with triglyc-
eride, apo B, HDL cholesterol and apo A-I concentrations, in
agreement with previous findings (51).
Conclusions. These data provide further support for the
role of oxidatively modified LDL in the pathogenesis of
coronary atherosclerosis and suggest that ox-LDL is involved
in the development of early changes of atherosclerosis by
affecting the coronary reactivity in young healthy men.
We thank the personnel of the Turku PET Center for their excellent technical
assistance.
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